Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. Our caring and courageous family aspires to enable brighter moments for patients and their loved ones. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. Our late-stage development efforts are focused on central nervous system disorders and Ret syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatri symptoms in central nervous system disorders. Visit our Booth No. #101. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.
Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com.
At our core is perseverance, a fierce determination to overcome any obstacle regardless of setbacks, on behalf of patients and their loved ones. We place greater value on what we can achieve together than on what we can do alone because the needs of those we serve always come first. We will not be bound by doing what’s been done before. Instead, we free ourselves from preconceived notions to discover solutions that advance patient care. Our mission is clear: Otsuka-people, creating new products for better health worldwide.
We are doing everything in our power to live up to our mission in three important categories.
Our driving philosophy at Otsuka is to serve those with unmet medical needs, and that couldn’t be more true than in our dedication to the central nervous system (CNS) space. In our 30 years of experience working in this therapeutic area, we continue to innovate and defy limitation by taking risks to overcome the complexities of treating mental health. We respect the value within every mind and are committed to making a difference in the lives of patients living with schizophrenia, major depressive disorder, bipolar disorder, and other CNS conditions.
When Otsuka saw a need for clinical expertise and research in the nephrology space, we decided to lead the way. For more than 20 years, we have been bringing our research and expertise to this therapeutic area. We have focused on developing novel drugs in areas of unmet need, such as autosomal dominant polycystic kidney disease and hyponatremia, that have changed the treatment landscape. Our long-term perseverance has led to major breakthroughs, giving patients renewed hope and clinicians more options than ever before.
Digital technology has not only changed the world we live in, but it is also changing the face of healthcare. Otsuka is at the forefront of this transformative juncture in medicine, creating novel solutions that help address the challenges of those living with serious mental illness. We believe our investment and leadership in this therapeutic area will revolutionize patient care as we know it. Patients will be able to engage and communicate with their care teams in new ways, and clinicians will have data-driven insights that may help inform treatment decisions.
OAPI and OPDC Locations
508 Carnegie Center Dr,
Princeton, NJ 08540, United States
2440 Research Blvd,
Rockville, MD 20850, United States
3956 Point Eden Way
Hayward, CA 94545, United States
30 Enterprise, Suite 200
Aliso Viejo, CA 92656, United States
We are Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives.
Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients.
We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. is united in our mission to deliver patient-needed therapies sooner.
Sumitomo Pharma America, Inc. is curious, bold, and share a passion for thinking differently.
Sumitomo Pharma America, Inc. Origins
SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliate companies including Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc., and Enzyvant Therapeutics, Inc. SMPA is a Sumitomo Pharma company.
Our parent company, Sumitomo Pharma Co., Ltd., was established in 1897 and has an extensive history of supporting health and wellbeing. Sumitomo Pharma is a member of the Sumitomo Group, which has a history of about 400 years. Learn more about Sumitomo Pharma’s history here.
VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and improving patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities.